Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Serum visfatin in chronic renal failure patients on maintenance hemodialysis: a correlation study

The Egyptian Journal of Internal Medicine volume 25, pages 202–208 (2013)Cite this article

Abstract

Background and aim of work

Endothelial dysfunction, atherosclerosis, and cardiovascular disease are strongly linked to chronic kidney disease. It has been hypothesized that visfatin may play an important role in uremia-related atherosclerosis and the relation between visfatin and endothelial dysfunction has been proved. We aimed to study and characterize the relation of visfatin to some clinical and biochemical parameters among chronic renal failure (CRF) patients on regular hemodialysis.

Patients and methods

This study was carried out on a total of 90 individuals, divided into two groups: group A included 68 patients with CRF on regular hemodialysis (44 men and 24 women) and group B included 22 healthy individuals as controls (four men and 18 women). All participants were subjected to the following: full clinical assessment, BMI assessment, FBS (Fasting blood sugar), PPBS (postprandial blood sugar), Hb level, lipid profile, serum urea, creatinine, potassium, phosphorus, and serum visfatin.

Results

Serum visfatin concentration was significantly high in group A (uremic on hemodialysis) compared with group B (control) (48.95 ng/ml ±11.62 compared with 22.65 ng/ml ± 5.24; P < 0.001); a highly significant positive correlation was found between serum visfatin and serum low-density lipoprotein (r = 0.39; P < 0.001) and a significant positive correlation between serum visfatin and serum triglycerides and serum uric acid (r = 0.28; P < 0.05 and r = −0.24; P < 0.05), respectively, whereas a highly significant negative correlation between serum visfatin and Hb (r = −0.43; P < 0.001) and a significant negative correlation between serum visfatin and serum urea (r = −0.25; P < 0.05), blood sugar, both fasting and postprandial (r = −0.34; P < 0.001 and r = −0.39; P < 0.001), respectively, were found in the patients in group A, without a significant correlation either to high-density lipoprotein, serum creatinine, the etiology of CRF, or to the duration of dialysis in the patients in group A.

Conclusion

This study proves the association of serum visfatin with CRF, unrelated to the biochemical parameter of kidney functions; however, further studies to examine visfatin expression within renal tissue may clarify its definitive role in CRF.

References

  1. Iglesias P, Díez JJ. Adipose tissue in renal disease: clinical significance and prognostic implications. Nephrol Dial Transplant 2010; 25: 2066–2077.

    Article  CAS  Google Scholar 

  2. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–430.

    Article  CAS  Google Scholar 

  3. Malam Z, Parodo J, Waheed F, Szaszi K, Kapus A, Marshall JC. Pre-B cell colony-enhancing factor (PBEF/Nampt/visfatin) primes neutrophils for augmented respiratory burst activity through partial assembly of the NADPH oxidase. J Immunol 2011; 186: 6474–6484.

    Article  CAS  Google Scholar 

  4. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007; 23: 164–170.

    Article  CAS  Google Scholar 

  5. Luk T, Malam Z, Marshal J. Pre-B cell colony enhancing factor (PBEF)/ visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008; 83: 804–816.

    Article  CAS  Google Scholar 

  6. Axelsson J, Witasp A, Carrero JJ, et al. Circulating levels of visfatin/ pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237–244.

    Article  CAS  Google Scholar 

  7. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959–965.

    Article  CAS  Google Scholar 

  8. Nüsken KD, Petrasch M, Rauh M, et al. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant 2009; 24: 2832–2838.

    Article  Google Scholar 

  9. Malyszko J, Malyszko S, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 2009; 41: 150–153.

    Article  CAS  Google Scholar 

  10. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008; 23: 1621–1627.

    Article  CAS  Google Scholar 

  11. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295: 1485–1494.

    Article  Google Scholar 

  12. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499.

    Article  Google Scholar 

  13. Garten A, Petzold S, Barnikol-Oettler A, Körner A, Thasler WE, Kratzsch J, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2010; 391: 376–381.

    Article  CAS  Google Scholar 

  14. Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Intern Med 2010; 21: 530–535.

    Article  CAS  Google Scholar 

  15. Mu J, Feng B, Ye Z, et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol 2011; 24: 177–184.

    Article  CAS  Google Scholar 

  16. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56: 565–570.

    Article  CAS  Google Scholar 

  17. Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169: 342–350.

    Article  Google Scholar 

  18. Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52: 39–48.

    Article  Google Scholar 

  19. Kambham N, Markowitz GS, Valeri AM. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498–1509.

    Article  CAS  Google Scholar 

  20. Tran HA. Obesity-related glomerulopathy. J Clin Endocrinol Metab 2004; 89: 6358.

    Article  CAS  Google Scholar 

  21. Mathew AV, Okada S, Sharma K. Obesity related kidney disease. Curr Diabetes Rev 2011; 7: 41–49.

    Article  CAS  Google Scholar 

  22. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002; 1: S28–S36.

    Google Scholar 

  23. C Leinig, R Pecoits-Filho, MM Nascimento, et al. Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients. J Ren Nutr 2008; 18: 424–429.

    Article  Google Scholar 

  24. JJ Carrero, A Witasp, P Stenvinkel, AR Qureshi, ME Suliman, L Nordfors, J Axelsson. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 2010; 25: 901–906.

    Article  CAS  Google Scholar 

  25. Mahmood N, Junejo AM, Jamal Q, Awan R. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes. J Pak Med Assoc 2010; 60: 922–926.

    PubMed  Google Scholar 

  26. Nüsken KD, Petrasch M, Rauh M, et al. Reduced plasma visfatin in end-stage renal disease is associated with reduced body fat mass and elevated serum insulin. Exp Clin Endocrinol Diabetes 2007; 115: P01–P052.

    Article  Google Scholar 

  27. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15: 1851–1862.

    Article  CAS  Google Scholar 

  28. Naz R, Hameed W, Hussain MM, Aslam M. Glucose lowering effect of visfatin in obese and insulin dependent. Pak J Physiol 2011; 7: 7-10.

    Google Scholar 

  29. Chumlea WC. Anthropometric and body composition assessment in dialysis patients. Semin Dial 2004; 17: 466–470.

    Article  Google Scholar 

  30. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin and endothelial function in dialyzed patients. Nephrology (Carlton) 2010; 15: 190–196.

    Article  CAS  Google Scholar 

  31. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?. Clin Transplant 2009; 23: 241–248.

    PubMed  Google Scholar 

  32. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007; 67: 796–800.

    Article  CAS  Google Scholar 

  33. Stenvinkel P. Inflammation in end-stage renal disease – a fire that burns within. Contrib Nephrol 2005; 149: 185–199.

    Article  Google Scholar 

  34. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur Heart J 2006; 27: 1174–1181.

    Article  CAS  Google Scholar 

  35. Lobo JC, Stockler-Pinto MB, Carraro-Eduardo JC, Mafra D. Is there association between uric acid and inflammation in hemodialysis patients? Ren Fail 2013; 35: 361–366.

    Article  CAS  Google Scholar 

  36. KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: 11–145.

    Article  Google Scholar 

  37. Orasan R, Awon R, Racasan S, Patiu M, Samasca G. Effects of l-carnitine on endothelial dysfunction, visfatin, oxidative stress, inflammation and anemia in hemodialysis patients. Acta Endocrinologica (Buc) 2011; VII: 219–228.

    Article  Google Scholar 

  38. Kaygusuz I. Gumus II, Yılmaz S, Simavlı S, Uysal S, Derbent A, et al. Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus. Gynecol Obstet Invest 2013; 75: 203–209.

    CAS  PubMed  Google Scholar 

  39. Van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008; 4: 47–57.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine for Boys, El Darassa, El Hussin Hospital, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt

    Abdel Wahab M. Lotfy MD

  2. Department of Internal Medicine for Girls, Al-Azhar University, Cairo, Egypt

    Hanan M. El-Tokhy & Fatma A. Attia

  3. Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt

    Nagwa A. Mohammed

Authors
  1. Abdel Wahab M. Lotfy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nagwa A. Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanan M. El-Tokhy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fatma A. Attia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdel Wahab M. Lotfy MD.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Lotfy, A.W.M., Mohammed, N.A., El-Tokhy, H.M. et al. Serum visfatin in chronic renal failure patients on maintenance hemodialysis: a correlation study. Egypt J Intern Med 25, 202–208 (2013). https://doi.org/10.4103/1110-7782.124982

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1110-7782.124982

Keywords